Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma

Mohammad Krayem¹, Ahmad Najem¹, Fabrice Journe^1,2, Renato Morandini¹, François Sales¹, Ahmad Awada³ and Ghanem E. Ghanem¹

¹Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
²Service d’Anatomie Humaine et d’Oncologie Expérimentale, Université de Mons, Mons, Belgium
³Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Published: June 03, 2024

This article has been retracted: Multiple internal duplications of western blot images illustrating the data of different experiments have been discovered throughout Figure 3C. In addition, Figure 3C also contains blots images from Figure 2A in an earlier published paper [1]. Therefore, with the agreement of all authors, the Scientific Integrity office at Oncotarget has decided to retract this paper.

REFERENCES

1. Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016; 55:98–110. https://doi.org/10.1016/j.ejca.2015.12.002. [PubMed].

Original article: Oncotarget. 2018; 9:31888–31903. DOI: https://doi.org/10.18632/oncotarget.25879